The Flow Cytometry and Cell Sorting Core will provide standard technology and analysis services to the Philadelphia ACE investigators. This core will be used by both research projects, both clinical components and the pilot research project. It is non-duplicative of other services or facilities available to ACE investigators. The Core will be built around a state-of-the-art sorting system that has fixed alignment of the three laser beams (for the blue, red, and UV lasers), which can perform multi-color analysis (up to 13) in a single cell and simultaneously sort 4 subpopulations with high purity, high recovery, high speed, and sterile cell sorting, thus being essential for the experiments proposed in projects by the Pis. The core resources are not otherwise available at the Thomas Jefferson University or through other grant mechanisms. Two certified specialists, including the Core Director and one full-time research assistant, will routinely run this core to provide high-quality service. The goals of the Flow Cytometry and Cell Sorting Core are to: 1) Offer high quality and affordably priced services for analysis and sorting of a range of cell types, with particular emphasis on immune cells according to the needs of autoimmunity investigators in the ACE;2) Consult with ACE members to determine their individual analytical cytometry needs, to aid in the development of appropriate protocols and techniques, giving advice for both standard and specialized services;3) Promote interaction and collaboration among investigators by providing a centralized facility where exchange of results and ideas will be facilitated. As flow cytometry will be extensively used by all the Pis, this well-equipped core, in both machine and personnel, will provide a powerful tool for the overall success of this ACE.
Due to the excellent capacity of FACSAria, particularly the multi-color analysis (up to 13) and high purity, high recovery, high speed and sterile cell sorting, this core is essential for the experiments proposed in projects by Drs. Rostami, Manser, Cohan, Leist, Jimenez, and Del Galdo. The core resources are not otherwise available at the Thomas Jefferson University or through other grant mechanisms.
|Xie, Chong; Ciric, Bogoljub; Yu, Shuo et al. (2016) IL-12RÎ²2 has a protective role in relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 291:59-69|
|Rasouli, Javad; Ciric, Bogoljub; Imitola, Jaime et al. (2015) Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-Î² Therapy. J Immunol 194:5085-93|
|Shao, Wen-Hai; Zhen, Yuxuan; Finkelman, Fred D et al. (2014) The Mertk receptor tyrosine kinase promotes T-B interaction stimulated by IgD B-cell receptor cross-linking. J Autoimmun 53:78-84|
|Fitzgerald, Denise C; Fonseca-Kelly, ZoÃ«; Cullimore, Melissa L et al. (2013) Independent and interdependent immunoregulatory effects of IL-27, IFN-Î², and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis. J Immunol 190:3225-34|
|Zizzo, Gaetano; Guerrieri, Justus; Dittman, Lindsay M et al. (2013) Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther 15:R212|
|Zizzo, Gaetano; Cohen, Philip L (2013) IL-17 stimulates differentiation of human anti-inflammatory macrophages and phagocytosis of apoptotic neutrophils in response to IL-10 and glucocorticoids. J Immunol 190:5237-46|
|Chen, David R; Cohen, Philip L (2012) Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis? Int J Clin Rheumtol 7:159-166|
|Zizzo, Gaetano; Hilliard, Brendan A; Monestier, Marc et al. (2012) Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunol 189:3508-20|
|Singh, Namrata; Cohen, Philip L (2012) The T cell in Sjogren's syndrome: force majeure, not spectateur. J Autoimmun 39:229-33|
|Finkel, Richard S; Crawford, Thomas O; Swoboda, Kathryn J et al. (2012) Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study. PLoS One 7:e35462|
Showing the most recent 10 out of 16 publications